ArticleInternational journal of nanomedicine2026
Identification of Bone Marrow and Peripheral Blood Plasma Extracellular Vesicle Protein Biomarker Signatures for Multiple Myeloma Diagnosis and Staging.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of abnormal plasma cells within the bone marrow (BM). Despite advances in treatment that have improved survival, the disease remains incurable. MM diagnosis requires invasive bone marrow biopsy to quantify the percentage of malignant plasma cells. In this study, the potential of extracellular vesicles (EVs) as a non-invasive liquid biopsy for MM diagnosis and staging was investigated, highlighting the diagnostic value of their proteomic biomarker cargo. Patients and Methods: Plasma-derived EVs from peripheral blood and bone marrow of 33 MM patients and 12 healthy donors were isolated, and their proteomic content was profiled via mass spectrometry. Biomarker signatures were identified using supervised machine learning to predict monoclonal gammopathy of undetermined significance (MGUS), progression to symptomatic MM, and relapse. Their discriminatory power was further evaluated through receiver operating characteristic curve analysis, and complementary performance metrics, including accuracy, sensitivity, specificity, predictive values, and F1 score. Significantly altered proteins were additionally assessed for functional enrichment in relevant biological pathways. Results: The analysis identified a six-protein biomarker signature, forming four optimal logistic regression diagnostic MM peripheral blood models with predictive accuracies of >85% and areas under the curve of >0.91. The signature was characterized by increased abundance of APOC1 and LGALS1 and decreased abundance of S100A7, CD226, ALAD, and KRT78, reflecting immune modulation, impaired immune surveillance, and disrupted proteostatic pathways. Conclusion: The performance of the identified proteins supports their potential as a minimally invasive EV-based liquid biopsy in MM diagnosis and monitoring, warranting future validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.